Savoxepin mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526251

CAS#: 79262-47-8 (mesylate)

Description: Savoxepin mesylate is a tetracyclic cyano-dibenzoxepino-azepine derivative with potent antidopaminergic activity.

Chemical Structure

img
Savoxepin mesylate
CAS# 79262-47-8 (mesylate)
Instruction

Theoretical Analysis

MedKoo Cat#: 526251
Name: Savoxepin mesylate
CAS#: 79262-47-8 (mesylate)
Chemical Formula: C26H30N2O4S
Exact Mass: 466.19
Molecular Weight: 466.600
Elemental Analysis: C, 66.93; H, 6.48; N, 6.00; O, 13.72; S, 6.87

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 79262-46-7 (free base)   79262-47-8 (mesylate),  

Synonym: Savoxepin mesylate; CGP 19486A; CGP-19486A; Savoxepin mesilate.

IUPAC/Chemical Name: 1H-Dibenz(2,3:6,7)oxepino(4,5-d)azepine-7-carbonitrile, 3-(cyclopentylmethyl)-2,3,4,5-tetrahydro-, methanesulfonate (1:1)

InChi Key: PDYLRPIUJQGVNY-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H26N2O.CH4O3S/c26-16-19-9-10-25-23(15-19)21-12-14-27(17-18-5-1-2-6-18)13-11-20(21)22-7-3-4-8-24(22)28-25;1-5(2,3)4/h3-4,7-10,15,18H,1-2,5-6,11-14,17H2;1H3,(H,2,3,4)

SMILES Code: N#CC1=CC=C(OC2=CC=CC=C23)C(C4=C3CCN(CC5CCCC5)CC4)=C1.CS(=O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 466.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Volz HP, Möller HJ, Gerebtzoff A, Bischoff S. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2002 Apr;252(2):76-80. PubMed PMID: 12111340.

2: Lefèvre G, Duval M, Botta L, Godbillon J. Direct microtitre plate radioimmunoassay of savoxepine in unextracted plasma. J Immunoassay. 1996 Feb;17(1):29-46. PubMed PMID: 8926305.

3: Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl). 1995 Jul;120(2):128-33. PubMed PMID: 7480543.

4: Cascella NG, Tarazi FI, Shirakawa O, Tamminga CA. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system. Psychopharmacology (Berl). 1994 Mar;114(2):275-80. PubMed PMID: 7838920.

5: Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res. 1993 Dec;10(12):1732-7. PubMed PMID: 7905625.

6: Leenders KL, Antonini A, Thomann R, Locher JT, Maître L, Gerebtzoff A, Beer HF, Ametamey S, Weinreich R, Gut A, et al. Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol. 1993;44(2):135-40. PubMed PMID: 8095895.

7: Herrmann WM, Schärer E, Wendt G, Delini-Stula A. Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry. 1991 Nov;24(6):214-24. PubMed PMID: 1812498.

8: Herrmann WM, Schärer E, Wendt G, Delini-Stula A. Pharmaco-EEG profile of levoprotiline: second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry. 1991 Nov;24(6):206-13. PubMed PMID: 1812497.

9: Herrmann WM, Schärer E, Delini-Stula A. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine. Pharmacopsychiatry. 1991 Nov;24(6):196-205. PubMed PMID: 1687485.

10: Wetzel H, Wiedemann K, Holsboer F, Benkert O. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology (Berl). 1991;103(2):280-3. PubMed PMID: 1674161.

11: Möller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry. 1989 Jan;22(1):38-41. PubMed PMID: 2565583.

12: Bischoff S, Christen P, Vassout A. Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):455-67. PubMed PMID: 2900538.

13: Butler B, Bech P. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report. Pharmacopsychiatry. 1987 May;20(3):122-6. PubMed PMID: 2885867.